Comparison of MELD, MELD-Na, and MELD 3.0 scoring systems for transplant prioritization in the Turkish population: A multicenter study
Kenan Moral(Unknown), Gokhan Kabacam(Güven Hospital), Haydar Adanır(Akdeniz University), Murat Dayangaç(Istanbul Medipol University), Mehmet Akif Yağli(Istanbul University), Dilara Turan Gökçe(Ankara Bilkent City Hospital), Murat Akyıldız(Koç University), Hale Gökcan(Ankara University), Mehmet Refik Goktug(Bursa Uludağ Üni̇versi̇tesi̇), Ramazan Idılman(Ankara University), Mesut Akarsu(Dokuz Eylül University), Murat Kekilli(Gazi University), Efe Erbay(Dokuz Eylül University), A. Nazari(Istanbul Medipol University), Onur Keskın(Ankara University), Meral Akdoğan Kayhan(Bilkent University), Murat Harputluoğlu(Inonu University), Derya Arı(Ankara Bilkent City Hospital), Gupse Adalı(Ümraniye Eğitim ve Araştırma Hastanesi), Mehmet Cindoruk(Gazi University), Zeki Karasu(Ege University), Osman Yüksekyayla(Harran University), Şencan Acar(Istanbul Florence Nightingale Hospital), Tarkan Karakan(Universitat Autònoma de Barcelona), Baver Ordu(Ümraniye Eğitim ve Araştırma Hastanesi), Fatih Eren(Bursa Uludağ Üni̇versi̇tesi̇), Burcu Gürbüz(Hacettepe University), Gulsah Fidan Ozkumur(Akdeniz University), N Yilmaz(Sanko University), Fulya Günşar, Zeynep Melekoglu Ellik(Ankara University), Genco Gencdal(Koç University), Murat Kıyıcı(Bursa Uludağ Üni̇versi̇tesi̇), Sabahattin Kaymakoğlu(Istanbul University), Alper Akın(Istanbul University), Elvan Işık(Ege University), Sezai Yilmaz(Inonu University), Nilay Danış(Dokuz Eylül University), Ahmet UYANIKOĞLU(Harran University), Doğancan Gavcar(Dokuz Eylül University), İlker Turan(Ege University)
Cited by 2
Related Papers
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
|Journal of Viral Hepatitis|2014|484
World Gastroenterology Organisation Global Guidelines
|Journal of Clinical Gastroenterology|2012|418
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
|Journal of Hepatology|2020|346
Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial
|The Lancet Infectious Diseases|2015|262